We evaluated the impact of maternal drug abuse at term on human placental cyto me P450 (CYP)-mediated (Phase I) xenobiotic and steroid-metabolizing activities [aromatase, 7-ethoxyre-sorufin O-deethylase (EROD), 7-etoxycoumarin Oadeethylase (ECOD), pyrene 1-hydroxylase (PIOH), and testosterone hydroxylasel, and androstenedione-forming isomerase, NADPH quinone oxidoreductase (Phae II), UDP-glucuronosyltransferase (UGT), and glutathione &trans-ferase (GST) activities in vitro. Overall, the formation of androstenedione, P1OH, and testosterone hydroxylase was statistically significant between control and drug-abusing subjects; we observed no significant differences in any other of the phase I and II activities. In placentas from drug-abusing mothers, we found sigificant correlations between ECOD and P1OH activities (p < 0.001), but not between ECOD and aromatase or P1OH and EROD actiities; we also found significant correlations between blood cotinine and UGT activities (p < 0.01). In contrast, in controls (mothers who did not abuse drugs but did smoke c s), the P1OH activity correlated with ECOD, EROD (p < 0.001), and testosterone hydroylae (p < 0.001) activities. Our results (wider variation in ECOD activity among tissue from drug-abusing mothers and the sigificant correlation between P10H and ECOD acttiviies, but not with aromatase or EROD activities) indicate that maternal drug abuse results in an additive effect in enhancing placental xenobiotic metabolizing enzymes when the mother also smokes cigaettes; this may be due to enhancing a "silent" CYP form, or a new placental CYP fonn may be activated. The change in the steroid metabolism profile in vib suggests that maternal drug abuse may alter normal hormonal homeostasis during pregnancy.
We evaluated the impact of maternal drug abuse at term on human placental cyto me P450 (CYP)-mediated (Phase I) xenobiotic and steroid-metabolizing activities [aromatase, 7-ethoxyresorufin O-deethylase (EROD), 7-etoxycoumarin Oadeethylase (ECOD), pyrene 1-hydroxylase (PIOH) , and testosterone hydroxylasel, and androstenedione-forming isomerase, NADPH quinone oxidoreductase (Phae II), UDP-glucuronosyltransferase (UGT), and glutathione &trans-ferase (GST) activities in vitro. Overall, the formation of androstenedione, P1OH, and testosterone hydroxylase was statistically significant between control and drug-abusing subjects; we observed no significant differences in any other of the phase I and II activities. In placentas from drug-abusing mothers, we found sigificant correlations between ECOD and P1OH activities (p < 0.001), but not between ECOD and aromatase or P1OH and EROD actiities; we also found significant correlations between blood cotinine and UGT activities (p < 0.01). In contrast, in controls (mothers who did not abuse drugs but did smoke c s), the P1OH activity correlated with ECOD, EROD (p < 0.001), and testosterone hydroylae (p < 0.001) activities. Our results (wider variation in ECOD activity among tissue from drug-abusing mothers and the sigificant correlation between P10H and ECOD acttiviies, but not with aromatase or EROD activities) indicate that maternal drug abuse results in an additive effect in enhancing placental xenobiotic metabolizing enzymes when the mother also smokes cigaettes; this may be due to enhancing a "silent" CYP form, or a new placental CYP fonn may be activated. The change in the steroid metabolism profile in vib suggests that maternal drug abuse may alter normal hormonal homeostasis during pregnancy. Illicit use of psychostimulants during pregnancy is an increasing problem in modern society, resulting in increased numbers of adverse pregnancy outcomes such as miscarriages, vaginal bleeding, and cognitive effects in newborns. However, the effect of maternal drug abuse on the metabolic characteristics of the human fetoplacental unit has not been evaluated thoroughly; therefore, the risk for underestimations or overestimations of metabolism-based outcomes is obvious.
Human placenta produces and metabolizes estrogenic steroids and metabolizes xenobiotics. Cytochrome P450 (CYP) enzymes participate in the synthesis and catabolism of steroid hormones; they also metabolize vitamins, fatty acids, and a wide range of medicinal drugs and chemical carcinogens (1, 2) . Human placental microsomal CYP enzymes catalyze the synthesis of estrogens (3) and metabolize and, in some cases, activate xenobiotic compounds (4) .
Human placenta at term expresses only a few functional xenobiotic-metabolizing CYP enzymes (4) (5) (6) . Thus far, only cigarette smoke-inducible CYPlAI (5) and ethanolinducible CYP2E1 (7) have been characterized at the protein and mRNA levels in human placenta, although at fill term CYPlAI, 2E1, 2F1, 3A4, 3A5, and 3A7 mRNAs can be detected (6) . Several drug therapies induding phenobarbital and phenobarbital-like inducers such as carbamazepine have failed to affect placental CYP-associated activities (8) (9) (10) .
In the present study, we examined the effect of maternal drug abuse on human placental xenobiotic-and steroid-metabolizing phase I and II activities at term in vitro. This is the first study to Preparation of placental samples. Immediately after delivery, a physical examination was performed and connective tissues and coagulated blood were removed. Placental tissue was rinsed in cold NaCl (0.9%) solution and gently dried between paper towels; small pieces of tissue (10 g) were taken from the central part of each placenta and immersed in liquid nitrogen. Placental samples were stored at -70°C until microsomes were prepared (within 2 months). To minimize decontamination of microsomes by mitchondrial fraction (11), microsomes were isolated and washed in 150 mM KCl, 10 mM EDTA buffer (pH 7.4) (12) and suspended in 100 mM potassium phosphate, 1 mM EDTA, 20% glycerol buffer (pH 7.4), to give the final protein content of 15-20 mg/mL (13) .
Biochemical assays. We determined microsomal protein concentrations by the bicinchonic acid method (14) . The following cytochrome P450-dependent metabolic reactions were determined using standard assays: 7-ethoxycoumarin O-deethylase activity (ECOD) was measured by the method of Greenlee and Poland (15) (18) using a substrate concentration of 10 nM.
The pyrene 1-hydroxylase (PIOH) assay mixture (270 ,uL final volume) contained 50 mM K-Na phosphate buffer-0. 15 After incubation at 37°C for 10 min, the reaction was stopped with 0.15% ZnSO4 . H20 and cooled on ice. After 600 jiL acetonitrile was added to the mixture, it was mixed for 10 sec and centrifuged for 10 min at 10,000 x g at 20C. We analyzed a 50-pL sample for 1-hydroxypyrene using a Spherisorb S3 OD (4.6 x 100 mm) column (Phase Separation Ltd, Deeside Industrial Park, UK), isocratic runs with acetonitrile-0.5% acetic acid in water (75: 25) , and a Shimadzu HPLC/CLASS VP 5.021 software chromatography data system (Shimadzu, Kyoto, Japan) equipped with an autoinjector and an RF-1 OA fluorometric detector (Xex 242 nm, Xem 388 nm). We used 1-hydroxypyrene calibration curves (0, 30, 60, 100, and 200 nM) for peak area quantification. The enzyme reaction was linear up to 30 min.
NADPH:quinone oxidoreductase (NQO) is a flavoprotein that catalyzes two-electron reduction of quinones and their derivatives, exerting a protective effect against chemical mutagenicity and toxicity. NQO was recorded at 600 nm as the dicoumarol (10 mM)-sensitive reduction of 2,6-dichlorophenolindophenol with NADPH as the electron donor. The assay mixture (1.2 mL), which contained 0.3-1 mg cytosolic protein from placental samples, was preincubated at 30'C for 5 min before addition of NADPH and the measurement in a Shimadzu 3,000 double beam spectrophotometer (Shimadzu) (19) .
Glutathione S-transferase (GST) activity toward 1-chloro-2,4-dinitrobenzene was recorded spectrophotometrically at room temperature according to Habig et al. (20) using 0.04.-0.12 mg cytosolic protein from placental samples in a 2.5-mL assay mixture.
We determined UGT activity toward 1-hydroxypyrene (93 pM) as the rate of microsomal glucuronidation at 37C in a 10-min assay according to the fluorometric HPLC method of Luukkanen et al. (21) . We used the Shimadzu HPLC apparatus described above for product identification and calibration of 1-hydroxypyrene-P-D-glucuronide.
Serum cotinine levels from maternal venous blood and umbilical cord blood samples were determined by the method of Kolonen and Puhakainen (22) Table 1 presents demographic data from mothers whose placentas were used in this study.
The comparison of xenobiotic-metabolizing activities and maternal venous and umbilical cord plasma cotinine concentrations from the drug-abusing group (the study group) and the cigarette-smoking controls are summarized in Table 2 . Briefly, of the phase I enzyme activities assayed in this Table 3 is a summary of the correlation matrix of all the determinations in the study group. Significant correlations existed only between PIOH and ECOD activities (p < 0.01), and between blood cotinine and microsomal UGT levels (p < 0.01). We found no significant correlation between P1GH and aromatase, P1OH and EROD, or P1OH and testosterone hydroxylation.
The correlation matrix containing determinations in the cigarette smoking control group is summarized in Table 4 Thus far, placental xenobiotic-metabolizing activities have been characterized primarily using cigarette smoking as a xenobiotic load (23) , whereas placentas from drug abusers have received only minor interest. However, contaminated food stuffs (24) and polluted air (25) may enhance placental xenobiotic-metabolizing activities, namely, In rodents, the hepatic GST activity increases due to xenobiotics. However, human placental GST does not seem enhanced, at least not because of cigarette smoking. We have shown that GST levels reflect the activity of steroid-metabolizing/ synthesizing functions (23) rather than indicate an increase in the xenobiotic load. The present results agree with our earlier study (23) ; placental GST levels decreased rather than increased in response to the maternal drug load. The phenomenon was identical when humans were exposed to industrial chemicals or radioactive ionization, both factors that enhance oxidative stress and decrease placental GST levels (26) .
UGT activity has been detected with a wide interindividual variation in human liver (27) and placenta (28) . An early study demonstrated that placental UGT activity does not positively correlate to maternal cigarette-smoking status (28) . According to our study in placenta, placental UGT activity responds to maternal cigarette smoking, detected by blood cotinine determinations, as decreased absolute enzymatic activity levels and a marginal positive correlation. However, in placentas from drug-abusing mothers, a strong correlation was observed. This is the first report to describe such a causality, suggesting that in the placenta the UGT activity does not readily respond to maternal cigarette smoking and, like the (31) (32) (33) (34) . However, the CYPJ9 gene is not affected by maternal cigarette smoking (23) or drinking of alcohol (35) . There is no significant correlation between P1OH and aromatase activities; this supports the view of the expression of a new catalytic activity.
Our earlier studies have shown that human placenta expresses more CYP genes at the mRNA level in the first trimester than at term (6, 36) . This may mean that at the phase of early development and growth of the fetoplacental unit, the expression of those CYP genes which are not urgently needed for the well-being of the human fetus could be switched off. However, maternal drug abuse could serve as a relevant enhancing stimulus to maintain the expression of specific CYP form(s) throughout the time of gestation.
Could these metabolic disturbances be reflected in later development of the affected fetus or child? An outstanding example of a compound that affected gestational hormonal homeostasis is diethylstilbestrol, with wellknown health effects appearing at adolescence. However, in these cases, no evaluation of placental xenobiotic or steroid-metabolizing capacity was carried out at delivery but only afterward, and no association for adverse events and placental metabolism could be demonstrated (37) .
During the 9 months of pregnancy, the human placenta passes through all its ontogenic developmental phases with the associated changes in its metabolic characteristics. During that period of growth and specialization, the human placenta is a potential target for unwanted metabolic responses caused by maternal diseases or xenobiotics. For example, maternal intrahepatic cholestasis of pregnancy has been shown to decrease overall placental metabolic capacity at term (38) , and maternal clinical use of corticosteroids dramatically suppresses placental aromatase at term (39) . However, the final clinical responses may be recorded only after a long delay, as with diethylstilbestrol. Responses such as these among drug abusers may be shown in future cohort studies.
Are there any implications to the current drug therapy during pregnancy? Results in the present study, generated using classical analytical methods, show no dramatic differences in metabolic characteristics or macroscopic characteristics between the study and control groups. However, in our extended panel of analysis, some significant correlations were observed. Maternal drug abuse caused an additive effect in xenobioticmetabolizing characteristics as compared to the cigarette-smoking control group. It is possible that the combination of drug abuse with any other medication could complicate the expression of placental metabolizing enzymes; these issues are still to be resolved. Therefore, all term placentas from mothers who use any relevant medication or abuse drugs should be evaluated in terms of total xenobiotic-metabolizing activity in vitro.
